Dongxing Zha

Company: Alloy Therapeutics

Job title: CEO of Keyway TCR Discovery

Seminars:

Keyway TCR-like Antibody (TCR mimic) Discovery: Fully Integrated Workflow to Get from Target Idea to Highly Specific & Functional Lead Candidate 8:55 am

• TCR-like antibody therapeutics (TCR mimics) enable the targeting of intracellular proteins (>70% of the human proteome) that have not been addressed by conventional cancer immunotherapies while avoiding the manufacturing and regulatory challenges of other TCRbased modalities. • Keyway TCRm Discovery is the industry leading service to deliver fully functional and highlyspecific lead TCRm candidates…Read more

day: Conference Day One